Compare Cytokinetics Inc (CYTK) vs First Trust Cloud Computing ETF (SKYY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs First Trust Cloud Computing ETF — how do they compare? Cytokinetics Inc trades at $62.91 (market cap $8.62B), while First Trust Cloud Computing ETF trades at $174.89 (market cap $3.47B). The key difference: Cytokinetics Inc is far larger — about 2.5× First Trust Cloud Computing ETF's market cap, and First Trust Cloud Computing ETF is trading nearer its 52-week high, Cytokinetics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and First Trust Cloud Computing ETF for 85 Days on average.
| CYTK | SKYY | |
|---|---|---|
Market Cap | $8.62B | $3.47B |
Volume | 2,594,626 | 176,159 |
Sector | Health | — |
52-Week High | $87.26 | $174.89 |
52-Week Low | $54.76 | $104.16 |
Typical Hold Time | 19 Days | 85 Days |
Enterprise Value | $8.72B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $62.01, up 1.46% today, amid bearish technical signals but strong analyst optimism. The stock shows negative profitability with a -1,321.12% net income margin and P/S ratio of 114, reflecting high growth expectations. Recent Phase 3 trial successes for aficamten in hypertrophic cardiomyopathy position the company for potential FDA approval and commercial expansion, driving the 97% buy rating consensus with a $112.60 price target.
The outlook balances clinical progress against financial strain. While aficamten's recent data and commercial launch of MYQORZO offer significant upside, persistent cash burn and high valuation multiples present substantial risk. Investors face binary outcomes dependent on regulatory success and market penetration versus ongoing operational losses.
First Trust Cloud Computing ETF (SKYY) trades at $170.14, down 0.37% on the day but near its 52-week high of $169.41. Technical indicators show a bullish trend with strong moving average support, while oscillators remain neutral. The ETF provides diversified exposure to cloud computing companies benefiting from AI adoption and digital transformation trends, with recent articles highlighting strong sector momentum.
The outlook remains positive given cloud computing's structural growth drivers, though valuation metrics are unavailable for analysis. Key risks include sector concentration and market volatility, while institutional activity shows mixed positioning. The ETF's focus on cloud infrastructure positions it well for continued AI-driven demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About First Trust Cloud Computing ETF
The fund will normally invest at least 90% of its net assets (including investment borrowings) in the common stocks and depositary receipts that comprise the index. The index is designed to track the performance of companies involved in the cloud computing industry.
Read more on SKYY →
